These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25088191)

  • 1. Discovery and optimization of 5-fluoro-4,6-dialkoxypyrimidine GPR119 agonists.
    Buzard DJ; Kim SH; Lehmann J; Han S; Calderon I; Wong A; Kawasaki A; Narayanan S; Bhat R; Gharbaoui T; Lopez L; Yue D; Whelan K; Al-Shamma H; Unett DJ; Shu HH; Tung SF; Chang S; Chuang CF; Morgan M; Sadeque A; Chu ZL; Leonard JN; Jones RM
    Bioorg Med Chem Lett; 2014 Sep; 24(17):4332-5. PubMed ID: 25088191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and optimization of N-(3-(1,3-dioxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yloxy)phenyl)benzenesulfonamides as novel GPR119 agonists.
    Yu M; Ken Zhang J; Wang Y; Zhu J; Kayser F; Medina JC; Siegler K; Conn M; Shan B; Grillo MP; Coward P; Jim Liu J
    Bioorg Med Chem Lett; 2014 Jan; 24(1):156-60. PubMed ID: 24332491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile.
    Semple G; Lehmann J; Wong A; Ren A; Bruce M; Shin YJ; Sage CR; Morgan M; Chen WC; Sebring K; Chu ZL; Leonard JN; Al-Shamma H; Grottick AJ; Du F; Liang Y; Demarest K; Jones RM
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1750-5. PubMed ID: 22264481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of small-molecule crystal structures to address solubility in a novel series of G protein coupled receptor 119 agonists: optimization of a lead and in vivo evaluation.
    Scott JS; Birch AM; Brocklehurst KJ; Broo A; Brown HS; Butlin RJ; Clarke DS; Davidsson O; Ertan A; Goldberg K; Groombridge SD; Hudson JA; Laber D; Leach AG; Macfaul PA; McKerrecher D; Pickup A; Schofield P; Svensson PH; Sörme P; Teague J
    J Med Chem; 2012 Jun; 55(11):5361-79. PubMed ID: 22545772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of 1H-pyrazolo[3,4-c]pyridine derivatives as a novel structural class of potent GPR119 agonists.
    Matsuda D; Kobashi Y; Mikami A; Kawamura M; Shiozawa F; Kawabe K; Hamada M; Oda K; Nishimoto S; Kimura K; Miyoshi M; Takayama N; Kakinuma H; Ohtake N
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3441-6. PubMed ID: 27390068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
    Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
    Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The optimization of xanthine derivatives leading to HBK001 hydrochloride as a potent dual ligand targeting DPP-IV and GPR119.
    Li G; Meng B; Yuan B; Huan Y; Zhou T; Jiang Q; Lei L; Sheng L; Wang W; Gong N; Lu Y; Ma C; Li Y; Shen Z; Huang H
    Eur J Med Chem; 2020 Feb; 188():112017. PubMed ID: 31926470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines as orally available G protein-coupled receptor 119 agonists.
    Katamreddy SR; Carpenter AJ; Ammala CE; Boros EE; Brashear RL; Briscoe CP; Bullard SR; Caldwell RD; Conlee CR; Croom DK; Hart SM; Heyer DO; Johnson PR; Kashatus JA; Minick DJ; Peckham GE; Ross SA; Roller SG; Samano VA; Sauls HR; Tadepalli SM; Thompson JB; Xu Y; Way JM
    J Med Chem; 2012 Dec; 55(24):10972-94. PubMed ID: 23214471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and optimization of arylsulfonyl 3-(pyridin-2-yloxy)anilines as novel GPR119 agonists.
    Zhang JK; Li AR; Yu M; Wang Y; Zhu J; Kayser F; Medina JC; Siegler K; Conn M; Shan B; Grillo MP; Eksterowicz J; Coward P; Liu JJ
    Bioorg Med Chem Lett; 2013 Jun; 23(12):3609-13. PubMed ID: 23648181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and optimization of 5-(2-((1-(phenylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)oxy)pyridin-4-yl)-1,2,4-oxadiazoles as novel gpr119 agonists.
    Wang Y; Yu M; Zhu J; Zhang JK; Kayser F; Medina JC; Siegler K; Conn M; Shan B; Grillo MP; Liu JJ; Coward P
    Bioorg Med Chem Lett; 2014 Feb; 24(4):1133-7. PubMed ID: 24440299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel xanthine compounds targeting DPP-IV and GPR119 as anti-diabetic agents.
    Li G; Huan Y; Yuan B; Wang J; Jiang Q; Lin Z; Shen Z; Huang H
    Eur J Med Chem; 2016 Nov; 124():103-116. PubMed ID: 27560285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2,5-Disubstituted pyridines as potent GPR119 agonists.
    Wu Y; Kuntz JD; Carpenter AJ; Fang J; Sauls HR; Gomez DJ; Ammala C; Xu Y; Hart S; Tadepalli S
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2577-81. PubMed ID: 20227877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a novel trans-1,4-dioxycyclohexane GPR119 agonist series.
    Han S; Narayanan S; Kim SH; Calderon I; Zhu X; Kawasaki A; Yue D; Lehmann J; Wong A; Buzard DJ; Semple G; Carroll C; Chu ZL; Al-Sharmma H; Shu HH; Tung SF; Unett DJ; Behan DP; Yoon WH; Morgan M; Usmani KA; Chen C; Sadeque A; Leonard JN; Jones RM
    Bioorg Med Chem Lett; 2015 Aug; 25(15):3034-8. PubMed ID: 26048791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and structure-activity relationship of fused-pyrimidine derivatives as a series of novel GPR119 agonists.
    Negoro K; Yonetoku Y; Moritomo A; Hayakawa M; Iikubo K; Yoshida S; Takeuchi M; Ohta M
    Bioorg Med Chem; 2012 Nov; 20(21):6442-51. PubMed ID: 23010456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and structure-activity relationship of dihydrobenzofuran derivatives as novel human GPR119 agonists.
    Ye XY; Morales CL; Wang Y; Rossi KA; Malmstrom SE; Abousleiman M; Sereda L; Apedo A; Robl JA; Miller KJ; Krupinski J; Wacker DA
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2539-45. PubMed ID: 24755425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel 3H-[1,2,3]triazolo[4,5-c]pyridine derivatives as GPR119 agonists: Synthesis and structure-activity/solubility relationships.
    Matsuda D; Kobashi Y; Mikami A; Kawamura M; Shiozawa F; Kawabe K; Hamada M; Nishimoto S; Kimura K; Miyoshi M; Takayama N; Kakinuma H; Ohtake N
    Bioorg Med Chem; 2017 Aug; 25(16):4339-4354. PubMed ID: 28662959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of structurally novel, potent and orally efficacious GPR119 agonists.
    Alper P; Azimioara M; Cow C; Mutnick D; Nikulin V; Michellys PY; Wang Z; Reding E; Paliotti M; Li J; Bao D; Zoll J; Kim Y; Zimmerman M; Groessel T; Tuntland T; Joseph SB; McNamara P; Seidel HM; Epple R
    Bioorg Med Chem Lett; 2014 May; 24(10):2383-7. PubMed ID: 24751443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes.
    Xia Y; Chackalamannil S; Greenlee WJ; Jayne C; Neustadt B; Stamford A; Vaccaro H; Xu XL; Baker H; O'Neill K; Woods M; Hawes B; Kowalski T
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3290-6. PubMed ID: 21536438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of pyrazolo[3,4-d]pyrimidine derivatives as GPR119 agonists.
    Gillespie P; Goodnow RA; Saha G; Bose G; Moulik K; Zwingelstein C; Myers M; Conde-Knape K; Pietranico-Cole S; So SS
    Bioorg Med Chem Lett; 2014 Feb; 24(3):949-53. PubMed ID: 24412066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel tricyclic pyrazolopyrimidines as potent and selective GPR119 agonists.
    Azimioara M; Alper P; Cow C; Mutnick D; Nikulin V; Lelais G; Mecom J; McNeill M; Michellys PY; Wang Z; Reding E; Paliotti M; Li J; Bao D; Zoll J; Kim Y; Zimmerman M; Groessl T; Tuntland T; Joseph SB; McNamara P; Seidel HM; Epple R
    Bioorg Med Chem Lett; 2014 Dec; 24(23):5478-83. PubMed ID: 25455488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.